Dr. James Brooks's group's interest is in developing diagnostic and prognostic markers for urological diseases. Their work spans discovery, measurement methodologies, and clinical validation of candidate biomarkers. They have primarily used genomic and proteomic approaches for biomarker discovery. While their primary focus has been in prostate cancer, we have also worked in kidney cancer and other malignancies.

Dr. Brooks's group is also working to characterize the functional roles of several of the candidate biomarkers in cancer. In the past several years their work has expanded into benign urologic diseases including benign prostatic hyperplasia, obstructive nephropathy, and androgen insensitivity syndrome. In collaboration with bioengineers and radiologists, they have active research in molecular imaging, and protein and nucleotide detection on biological samples. They also participate in several large clinical trials for development, validation and implementation of clinical biomarkers in prostate cancer.